Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.

Stéphanie LheureuxDaniela E MateiPanagiotis A KonstantinopoulosBen X WangRamy GadallaMatthew S BlockAndrea JewellStephanie L GaillardMichael McHaleCarolyn McCourtSarah TemkinEugenia GirdaFloor J BackesTheresa L WernerLinda DuskaSiobhan KehoeIlaria ColomboLisa WangXuan LiRachel WildmanShirin SoleimaniScott LienJohn WrightTrevor PughPamela S OhashiDavid G BrooksGini F Fleming

Published in: Journal for immunotherapy of cancer (2022)

Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune profile and potentially benefiting from combination with antiangiogenics requires further investigation.

Keyphrases

endometrial cancer
end stage renal disease
open label
newly diagnosed
small cell lung cancer
chronic kidney disease
squamous cell carcinoma
phase iii
peritoneal dialysis
prognostic factors
adipose tissue
patient reported outcomes
phase ii
metastatic renal cell carcinoma
insulin resistance